|8:30||Arrival, coffee and get-together|
|8:45||Welcome and introduction about ULTRA-DD
Michael Sundstrom (Karolinska)
|9:00||The importance of jointly funded translational medicine IMI projects|
|9:15||Target selection and prioritization
Julian Knight et al. (Oxford)
|9:45||Converting prioritized targets into protein samples and antibody research tools
Nicola Burgess-Brown (Oxford) and Susanne Gräslund (Karolinska) et al.
|10:15||Predictive cell-based assays as a foundation for research tool identification and generation
Gillian Farnie, Kilian Huber, Oleg Fedorov (Oxford) et al.
|11:00||Shedding light on protein structure and function
Katharina Duerr, Liz Carpenter, Frank von Delft (Oxford) and Matthias Gstaiger (ETH Zurich) et al.
|11:30||Generating high quality chemical probes for target validation
Paul Brennan (Oxford) et al.
|12:00||Better translational assays based on patient material
Louise Berg (Karolinska), Fiona McCann (Oxford) et al.
|12:00||Maximinsing impact: communication of results and creating research networks
Brian Marsden, Wen Hwa Lee (Oxford) et al.
|13:00||Lunch and Networking|
|Showcase on Collaborative Initiatives with ULTRA-DD|
|14:00||Boehringer-Ingelheim’s approach to Open Science
Adrian Carter (Corporate VP and Global Head Discovery Research Coordination)
|14:20||Research and clinical aspects of IBD
Ola Winqvist (Professor of cellular immunotherapy, KI)
|14:40||Drug Development and Discovery Platform at Science for Life Laboratory at Karolinska Institutet
Per Arvidsson (Exec. Director Drug Discovery & Development, Science for Life)
|15:00||The IMI European Lead Factory (ELF)
Jon de Vlieger (Business developer Lygature/ ELF)
|15:30||The merits of Open Science – Panel Discussion|
|16:00||Wrap-up and end of meeting|